Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Doxazosin, an alpha(1)-adrenergic antihypertensive agent, decreases serum oxidized LDL
Autore:
Kinoshita, M; Shimazu, N; Fujita, M; Fujimaki, Y; Kojima, K; Mikuni, Y; Horie, E; Teramoto, T;
Indirizzi:
Teikyo Univ, Sch Med, Dept Internal Med, Tokyo 1738605, Japan Teikyo UnivTokyo Japan 1738605 Dept Internal Med, Tokyo 1738605, Japan
Titolo Testata:
AMERICAN JOURNAL OF HYPERTENSION
fascicolo: 3, volume: 14, anno: 2001,
pagine: 267 - 270
SICI:
0895-7061(200103)14:3<267:DAAAAD>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DENSITY-LIPOPROTEIN; ACUTE CORONARY SYNDROMES; MONOCLONAL-ANTIBODY; OXIDATIVE MODIFICATION; ARTERY DISEASE; HUMAN PLASMA; CELLS; PHOSPHATIDYLCHOLINES; ATHEROSCLEROSIS; SUPPLEMENTATION;
Keywords:
atherosclerosis; doxazosin; oxidized low-density lipoprotein;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Kinoshita, M Teikyo Univ, Sch Med, Dept Internal Med, 2-11-1 Kaga, Tokyo 1738605, Japan Teikyo Univ 2-11-1 Kaga Tokyo Japan 1738605 o 1738605, Japan
Citazione:
M. Kinoshita et al., "Doxazosin, an alpha(1)-adrenergic antihypertensive agent, decreases serum oxidized LDL", AM J HYPERT, 14(3), 2001, pp. 267-270

Abstract

Oxidized low-density lipoprotein (ox-LDL) is well known to play an important role in atherogenesis through the recruitment of monocytes into vessel walls and the deposition of cholesterol ester in the macrophages, which leads to the formation of lipid-rich plaque. It was assumed that only trace amounts of ox-LDL were present in plasma because the half-life of ox-LDL was only a few minutes. Recently, through the use of a monoclonal antibody against ox-LDL, a quantitative method to measure serum ox-LDL concentration has been developed. Metabolites of doxazosin, an alpha (1)-adrenergic antihypertensive agent, have been reported to inhibit oxidation of LDL in vitro. In this study, we investigated the in vivo effect of doxazosin on LDL oxidation using this new method to measure serum ox-LDL concentration. After the administration of doxazosin for 1 to 2 months, serum concentration of ox-LDL decreased significantly (P < .05). Although the reduction of ox-LDL concentration does not strictly indicate doxazosin's antiatherosclerotic effect, it may constitute one of doxazosin's additional weapons beside lowering blood pressure and serum lipid values in the prevention of atherosclerosis. (C)2001 American Journal of Hypertension, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 08:15:55